Literature DB >> 23181170

Structure-selective anisotropy assay for amyloid Beta oligomers.

Evgenia G Matveeva1, Alan Rudolph, Jonathan R Moll, Richard B Thompson.   

Abstract

Amyloid β (Abeta) peptides in their oligomeric form have been proposed as major toxic species in Alzheimer's disease (AD). There are a limited number of anti-Abeta antibodies specific to oligomeric forms of Abeta compared to the monomeric form, and accurate measurement of oligomeric forms in biological samples, cerebrospinal fluid (CSF), or brain extracts remains challenging. We introduce an oligomer-specific (in preference to monomers or fibrils) fluorescence assay based on a conformationally sensitive bis-pyrene-labeled peptide that contains amino acid residues 16-35 of the human amyloid beta protein (pronucleon peptide, PP). This peptide exhibits a shift in fluorescence emission from pyrene excimer to pyrene monomer emission resulting from a conformational change. Specific binding of PP to oligomeric forms of Abeta can be monitored in solution by a change in fluorescence spectrum as well as a change in pyrene monomer fluorescence anisotropy (or polarization). The mechanism of binding and its relation to anisotropy and fluorescence lifetime changes are discussed. The development of a simple, rapid, anisotropy assay for measurement of Abeta oligomers is important for further study of the oligomers' role in AD, and specific detection of oligomers in biological samples, such as cerebrospinal fluid.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23181170      PMCID: PMC3504480          DOI: 10.1021/cn3001262

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  22 in total

1.  High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.

Authors:  Hiroaki Fukumoto; Takahiko Tokuda; Takashi Kasai; Noriko Ishigami; Hiroya Hidaka; Masaki Kondo; David Allsop; Masanori Nakagawa
Journal:  FASEB J       Date:  2010-03-25       Impact factor: 5.191

2.  Rapid presymptomatic detection of PrPSc via conformationally responsive palindromic PrP peptides.

Authors:  A Grosset; K Moskowitz; C Nelsen; T Pan; E Davidson; C S Orser
Journal:  Peptides       Date:  2005-04-14       Impact factor: 3.750

Review 3.  Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses.

Authors:  Waldo Cerpa; Margarita C Dinamarca; Nibaldo C Inestrosa
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

4.  Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies.

Authors:  Heinz Hillen; Stefan Barghorn; Andreas Striebinger; Boris Labkovsky; Reinhold Müller; Volker Nimmrich; Marc W Nolte; Claudia Perez-Cruz; Ingrid van der Auwera; Fred van Leuven; Marcel van Gaalen; Anton Y Bespalov; Hans Schoemaker; James P Sullivan; Ulrich Ebert
Journal:  J Neurosci       Date:  2010-08-04       Impact factor: 6.167

5.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.

Authors:  Stefan Barghorn; Volker Nimmrich; Andreas Striebinger; Carsten Krantz; Patrick Keller; Bodo Janson; Michael Bahr; Martin Schmidt; Robert S Bitner; John Harlan; Eve Barlow; Ulrich Ebert; Heinz Hillen
Journal:  J Neurochem       Date:  2005-08-31       Impact factor: 5.372

6.  Antimicrobial peptides for detection of bacteria in biosensor assays.

Authors:  Nadezhda V Kulagina; Michael E Lassman; Frances S Ligler; Chris Rowe Taitt
Journal:  Anal Chem       Date:  2005-10-01       Impact factor: 6.986

7.  Synaptic targeting by Alzheimer's-related amyloid beta oligomers.

Authors:  Pascale N Lacor; Maria C Buniel; Lei Chang; Sara J Fernandez; Yuesong Gong; Kirsten L Viola; Mary P Lambert; Pauline T Velasco; Eileen H Bigio; Caleb E Finch; Grant A Krafft; William L Klein
Journal:  J Neurosci       Date:  2004-11-10       Impact factor: 6.167

Review 8.  Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

Authors:  Christopher D Aluise; Renã A Sowell; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2008-08-07

9.  Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding.

Authors:  Andrea C Klaver; Lynnae M Patrias; Mary P Coffey; John M Finke; David A Loeffler
Journal:  J Neurosci Methods       Date:  2010-01-25       Impact factor: 2.390

10.  Antimicrobial peptides as new recognition molecules for screening challenging species.

Authors:  Nadezhda V Kulagina; Kara M Shaffer; Frances S Ligler; Chris R Taitt
Journal:  Sens Actuators B Chem       Date:  2007-01-30       Impact factor: 7.460

View more
  4 in total

1.  Fluorescence polarization assays in high-throughput screening and drug discovery: a review.

Authors:  Matthew D Hall; Adam Yasgar; Tyler Peryea; John C Braisted; Ajit Jadhav; Anton Simeonov; Nathan P Coussens
Journal:  Methods Appl Fluoresc       Date:  2016-04-28       Impact factor: 3.009

Review 2.  Fluorescence anisotropy (polarization): from drug screening to precision medicine.

Authors:  Hairong Zhang; Qian Wu; Mikhail Y Berezin
Journal:  Expert Opin Drug Discov       Date:  2015-08-03       Impact factor: 6.098

3.  Fabrication of an antibody-aptamer sandwich assay for electrochemical evaluation of levels of β-amyloid oligomers.

Authors:  Yanli Zhou; Huanqing Zhang; Lantao Liu; Congming Li; Zhu Chang; Xu Zhu; Baoxian Ye; Maotian Xu
Journal:  Sci Rep       Date:  2016-10-11       Impact factor: 4.379

4.  A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles.

Authors:  Yun Xing; Xiao-Zhen Feng; Lipeng Zhang; Jiating Hou; Guo-Cheng Han; Zhencheng Chen
Journal:  Int J Nanomedicine       Date:  2017-04-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.